HHS, Defense Department invest in manufacturing demonstration to produce 100 million COVID-19 investigational vaccine doses
The Department of Health and Human Services today announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.
The investment is expected to yield 100 million fill-finished doses, meaning vaccine doses are packaged and ready to ship immediately if clinical trials are successful and the Food and Drug Administration authorizes its use.
Related News Articles
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…